SCHEMBL24257773

SCHEMBL24257773

Cc1c(-c2cccc(Oc3ccccc3)c2)cnc(C#N)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.44
PIN1 Q13526 1/20 0.40
NR1H2 P55055 2/20 0.40
NR1H3 Q13133 2/20 0.40
CYP1A2 P05177 4/20 0.39
CYP2C19 P33261 3/20 0.39
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP2C9 P11712 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ERBB2 P04626 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
GRIN2D O15399 2/20 0.36
GRIN3B O60391 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2A Q12879 2/20 0.36
GRIN2B Q13224 2/20 0.36
GRIN2C Q14957 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257700 0.88 BTK (0.54) BTKALDH1A1MEN1KMT2AADORA2A
SCHEMBL30453695 0.88 BTK (0.54) BTKALDH1A1MEN1KMT2AADORA2A
SCHEMBL24257698 0.82 DHFR (0.44) ALDH1A1MEN1KMT2AADORA2AADORA1
SCHEMBL30454648 0.82 DHFR (0.44) ALDH1A1MEN1KMT2AADORA2AADORA1
SCHEMBL24257731 0.82 LRRK2 (0.42) BTKCYP1A2CYP2C19ALDH1A1MEN1
SCHEMBL24257522 0.81 SQOR (0.40) NR1H2NR1H3CYP1A2CYP2C19ALDH1A1
SCHEMBL24257730 0.80 NPSR1 (0.41) BTKALDH1A1L3MBTL1ADORA2AADORA1
SCHEMBL30453225 0.80 NPSR1 (0.41) BTKALDH1A1L3MBTL1ADORA2AADORA1
SCHEMBL24257623 0.80 DHFR (0.43) BTKCYP1A2CYP2C19ALDH1A1CYP2C9
SCHEMBL30546851 0.80 DHFR (0.43) BTKCYP1A2CYP2C19ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 BTK 1309/4885PIN1 1231/4885NR1H2 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.